Penumbra, Inc. (PEN)
- Previous Close
237.11 - Open
235.29 - Bid --
- Ask 382.72 x 800
- Day's Range
235.59 - 239.52 - 52 Week Range
148.00 - 277.34 - Volume
248,864 - Avg. Volume
386,266 - Market Cap (intraday)
9.18B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
278.14 - EPS (TTM)
0.86 - Earnings Date Feb 20, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
235.07
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
www.penumbrainc.comRecent News: PEN
View MorePerformance Overview: PEN
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEN
View MoreValuation Measures
Market Cap
9.18B
Enterprise Value
9.12B
Trailing P/E
274.94
Forward P/E
64.94
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.99
Price/Book (mrq)
8.31
Enterprise Value/Revenue
7.83
Enterprise Value/EBITDA
214.20
Financial Highlights
Profitability and Income Statement
Profit Margin
2.97%
Return on Assets (ttm)
3.33%
Return on Equity (ttm)
3.13%
Revenue (ttm)
1.16B
Net Income Avi to Common (ttm)
34.55M
Diluted EPS (ttm)
0.86
Balance Sheet and Cash Flow
Total Cash (mrq)
291.02M
Total Debt/Equity (mrq)
20.53%
Levered Free Cash Flow (ttm)
125.27M